Product Highlight - Mibeaz

29 Sep 2021
Product Highlight - Mibeaz
Active Ingredient: Ezetimibe.
• Adjunctive therapy for treatment of primary hyperlipidemia.
• Prevention of CVD.
• Prevention of major CVE in CKD patients.
• Homozygous familial hypercholesterolemia and homozygous familial sitosterolemia by decreasing elevated serum lipids and/or sterol concentration. Along with reducing risk of cardiovascular events.
Dosage & Administration: The recommended dose of MIBEAZ tablet is 10 mg OD (with or without food).
Presentation: Tab 10 mg x 3 x 10’s.

Related MIMS Drugs

Editor's Recommendations